OrbiMed Reveals 7.2% Stake in Scribe Therapeutics, Assembled via IPO and Preferred Conversion
SCTX is trading near its 52-week low of $17.305 (6.9% above the low).
Summary
OrbiMed Advisors disclosed a 7.2% stake in Scribe Therapeutics, built through a $15 million IPO purchase and conversion of $31 million in preferred stock. The filing confirms a major institutional backer with board representation.
Key Events · Ownership and Investor Activity · SCTX
-
OrbiMed Builds 7.2% Stake
OrbiMed Advisors and OrbiMed Capital GP VIII acquired 1,348,825 shares, representing 7.2% of Scribe's outstanding common stock, through a combination of Series B preferred stock conversion and IPO purchases.
-
Stake Valued at ~$25M at IPO Price
The position was built via 2,065,672 Series B preferred shares (converted at 1-for-0.1689 into 348,825 common shares) and 1,000,000 shares bought in the IPO at $15.00 each, for a total cost basis of approximately $46 million.
-
Board Representation
Carl L. Gordon, a member of OrbiMed Advisors, serves on Scribe's board of directors, giving the investment group direct influence over corporate strategy.
-
180-Day Lock-Up Restricts Immediate Sales
All shares are subject to a 180-day lock-up agreement expiring in late January 2027, preventing any near-term selling pressure from this stake.
Analysis · SCTX · Life Sciences
Just days after Scribe Therapeutics went public, OrbiMed Advisors—a leading healthcare investment firm—has accumulated a 7.2% stake. The position combines a $15 million IPO purchase at $15.00 per share with the conversion of $31 million in Series B preferred stock. Because OrbiMed partner Carl Gordon sits on Scribe's board, this represents a powerful institutional endorsement from a specialist investor. However, the 180-day lock-up means the overhang won't hit the market until late January 2027.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCTX was trading at $18.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $297.1M. The 52-week trading range was $17.31 to $22.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.